OSCR
Oscar Health, Inc.
OSCR has the edge over RXST overall, supported by stronger fundamentals.
RXST
RxSight, Inc.
RXST's outlook is improving, though it still trails on the overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RXST Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
RXST's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RXST PE Valuation
RXST has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RXST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RXST's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RXST on earnings quality, reporting a profit while its opponent remains loss making.
RXST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.41 |
| Q2 2026 | -$1.13 | -$0.34 |
| Q1 2026 | -$1.13 | -$0.47 |
| Q4 2025 | -$0.95 | -$0.24 |
| Q3 2025 | -$0.87 | -$0.06 |
| Q2 2025 | -$0.79 | +$0.21 |
| Q1 2025 | -$0.66 | +$0.58 |
| Q4 2024 | -$0.71 | +$0.70 |
RXST is still losing money, but far less than before: $1.28 per share over the past year, against $3.19 at its worst in late 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RXST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RXST on profitability, with a higher operating margin.
RXST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -19% |
| Q2 2026 | $33.7M | +0.3% |
| Q1 2026 | $30.9M | -18% |
| Q4 2025 | $32.6M | -19% |
| Q3 2025 | $30.3M | -14% |
| Q2 2025 | $33.6M | -3.6% |
| Q1 2025 | $37.9M | +28% |
| Q4 2024 | $40.2M | +41% |
RXST's revenue has slid since its 2024 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -35 points |
| Q2 2026 | -41% | +0.8 points |
| Q1 2026 | -58% | -30 points |
| Q4 2025 | -35% | -13 points |
| Q3 2025 | -40% | -14 points |
| Q2 2025 | -42% | -18 points |
| Q1 2025 | -28% | +8 points |
| Q4 2024 | -21% | +17 points |
RXST's operating margin was −75% last quarter, down 35 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RXST on cash flow, with more consistent year-over-year improvement.
RXST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44M | +$45.8M |
| Q2 2026 | -$11.5M | -$5.6M |
| Q1 2026 | -$11.7M | -$2.2M |
| Q4 2025 | -$2.3M | +$2.9M |
| Q3 2025 | -$1.8M | -$1.3M |
| Q2 2025 | -$5.9M | -$363K |
| Q1 2025 | -$9.4M | +$1.9M |
| Q4 2024 | -$5.1M | +$4.8M |
RXST's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RXST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +215K shares |
| 1 year | +1.8% | +740K shares |
| 3 years | +17% | +6M shares |
| 5 years | +901% | +37.5M shares |
| Available history | +119% | +22.6M shares |
RXST has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RXST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.5x | Very low |
RXST's net debt is less than a year of its operating earnings (EBITDA).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RXST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 22.2 | Neutral |
RXST's weekly RSI is 47 (neutral) and its Stochastic is 22 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RXST PE vs Healthcare Sector
RXST has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RXST on trend strength, trading above more of its moving averages.
RXST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.81 | 12% above |
| 20 week MA | $5.49 | 2% below |
| 50 week MA | $6.88 | 22% below |
| 100 week MA | $11.9 | 55% below |
| 200 week MA | $24.9 | 78% below |
RXST has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 78% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RXST on returns for 2026, with the stronger performance.
RXST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.0 | $10.6 | -34% |
| 2022 | $10.6 | $11.9 | +12% |
| 2023 | $11.9 | $40.3 | +239% |
| 2024 | $40.3 | $34.2 | -15% |
| 2025 | $34.2 | $10.9 | -68% |
| 2026 YTD | $10.9 | $5.38 | -51% |
RXST's yearly returns have swung widely, from +239% in 2023 to −68% in 2025. It's down 51% so far in 2026.